文献速递血栓与止血

妊娠期免疫性血小板减少症的血小板生成素受体激动剂治疗

Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists.
PubMed 文献 · Br J Haematol · 2023-10-13

该综述分析45例妊娠期免疫性血小板减少症(ITP)患者使用血小板生成素受体激动剂(TPO-RA)的安全性和有效性,其中罗米司亭22例、艾曲泊帕21例、同一妊娠期两者均用2例。血小板应答(>30×10^9/L)见于86.7%的病例,艾曲泊帕与罗米司亭相似(87.0% vs 83.3%,p=0.99)。母体安全性良好,无血栓栓塞事件;新生儿血小板减少见于三分之一病例,包括1例3级颅内出血,新生儿血小板增多3例。综述提示TPO-RA在妊娠期应答率高且似乎安全,但不应常规使用,且在积累更多证据前应避免在妊娠早期使用。

要点

  • 妊娠期ITP使用TPO-RA的血小板应答率(>30×10^9/L)为86.7%,其中完全应答(>100×10^9/L)为66.7%。
  • 艾曲泊帕与罗米司亭的应答率相似(87.0% vs 83.3%,p=0.99)。
  • 母体无血栓栓塞事件,新生儿血小板减少见于三分之一病例,包括1例3级颅内出血。

核心结论

  • 该综述提示妊娠期使用TPO-RA与高应答率相关且似乎安全,但TPO-RA不应常规用于妊娠期,且在积累更多证据前应避免在妊娠早期使用。

研究设计与样本

  • 该综述纳入45例妊娠期ITP患者使用TPO-RA的病例,其中罗米司亭22例、艾曲泊帕21例、同一妊娠期两者均用2例。

主要发现

  • 血小板应答(>30×10^9/L)见于86.7%的病例,包括完全应答(>100×10^9/L)66.7%。
  • 艾曲泊帕与罗米司亭的应答率相似(87.0% vs 83.3%,p=0.99)。
  • 母体安全性良好,未发生血栓栓塞事件。
  • 新生儿血小板减少见于三分之一病例,包括1例3级颅内出血;新生儿血小板增多3例。
  • 未观察到其他归因于TPO-RA的新生儿不良事件。

关键数值与推荐

  • 血小板应答定义为>30×10^9/L,完全应答定义为>100×10^9/L。
  • 艾曲泊帕组应答率87.0%,罗米司亭组83.3%,两组比较p=0.99。

临床怎么用

  • 该综述建议TPO-RA不应常规用于妊娠期,且在积累更多证据前应避免在妊娠早期使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of thrombopoietin receptor agonists (TPO-RAs) led to a paradigm shift in the management of immune thrombocytopenia (ITP). However, TPO-RAs are not approved for use during pregnancy due to the absence of evidence and concerns for possible effects on the fetus due to their expected transplacental transfer. This comprehensive review examines the safety and efficacy of TPO-RA in 45 pregnancies of women with ITP (romiplostim n = 22; eltrombopag n = 21; both in the same pregnancy n = 2). Mothers experienced failure of the median of three treatment lines during pregnancy prior to TPO-RA administration. A platelet response (>30 × 109 /L) was seen in 86.7% of cases (including a complete response >100 × 109 /L in 66.7%) and was similar between eltrombopag and romiplostim (87.0% and 83.3%, p = 0.99). The maternal safety profile was favourable, with no thromboembolic events encountered. Neonatal thrombocytopenia was noted in one third of cases, with one case of ICH grade 3, and neonatal thrombocytosis was observed in three cases. No other neonatal adverse events attributable to TPO-RAs were seen. This review suggests that the use of TPO-RA during pregnancy is associated with a high response rate and appears safe. Nevertheless, TPO-RA should not be routinely used in pregnancy and should be avoided in the first trimester until further evidence is accumulated.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rottenstreich A, Bussel JB. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists. Br J Haematol. 2023. PMID: 37830251. doi:10.1111/bjh.19161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。